<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275339</url>
  </required_header>
  <id_info>
    <org_study_id>10-1334b</org_study_id>
    <nct_id>NCT01275339</nct_id>
  </id_info>
  <brief_title>Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study</brief_title>
  <acronym>ASPEN</acronym>
  <official_title>Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, aortic stenosis (AS) is considered a &quot;surgical disease&quot; with no medical therapy
      available to improve any clinical outcomes, including symptoms, time to surgery, or long-term
      survival. Thus far, randomized studies involving statins have not been promising with respect
      to slowing progressive valve stenosis. Beyond the valve, two common consequences of aortic
      stenosis are hypertrophic remodeling of the left ventricle (LV) and pulmonary venous
      hypertension; each of these has been associated with worse heart failure symptoms, increased
      operative mortality, and worse long-term outcomes. Whether altering LV structural
      abnormalities, improving LV function, and/or reducing pulmonary artery pressures with medical
      therapy would improve clinical outcomes in patients with AS has not been tested. Animal
      models of pressure overload have demonstrated that phosphodiesterase type 5 (PDE5) inhibition
      influences nitric oxide (NO) - cyclic guanosine monophosphate (cGMP) signaling in the LV and
      favorably impacts LV structure and function, but this has not been tested in humans with AS.
      Studies in humans with left-sided heart failure and pulmonary venous hypertension have shown
      that PDE5 inhibition improves functional capacity and quality of life, but patients with AS
      were not included in those studies. The investigators hypothesize that PDE5 inhibition with
      tadalafil will have a favorable impact on LV structure and function as well as pulmonary
      artery pressures. In this pilot study, the investigators anticipate that short-term
      administration of tadalafil to patients with AS will be safe and well-tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with moderately severe to severe aortic stenosis (AS), left ventricular hypertrophy
      (LVH), diastolic dysfunction, preserved ejection fraction, and no planned aortic valve
      replacement over the next 6 months will be eligible for this randomized, double-blind,
      placebo-controlled, pilot study. There will be a diabetic cohort (n=32) and non-diabetic
      cohort (n=24); each cohort will be randomized 1:1 to tadalafil vs. placebo. During a baseline
      study visit, the following will be obtained: clinical data, 6 minute walk, quality of life
      questionnaire, blood draw, and an echocardiogram. A 3-day run-in will occur to initially
      assess tolerability and compliance. If the drug is tolerated during this run-in period,
      participants will be randomized. An MRI will also be performed during this randomization
      visit. Follow-up study visits and testing will occur at 6 and 12 weeks and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty enrolling patients and PI moved institutions.
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 14, 2017</completion_date>
  <primary_completion_date type="Actual">April 14, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diastolic Function as Measured by Tissue Doppler e'</measure>
    <time_frame>Baseline, 12 weeks, and 6 months</time_frame>
    <description>Measurement of e' (average of septal and lateral) on echo at each of the time points specified.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Myocardial Fibrosis (ECV) on MRI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Other Echocardiographic Indices of Diastolic Function</measure>
    <time_frame>12 weeks and 6 months</time_frame>
    <description>E/e' and deceleration time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>6 and 12 weeks and 6 months</time_frame>
    <description>The following with be reported - frequency of the following: hypotension (SBP &lt; 90 mmHg), symptomatic hypotension (symptoms of presyncope or syncope associated with SBP &lt;90), syncope, hospitalization for a cardiac reason, myocardial infarction, new onset or worsening heart failure, and new sustained arrhythmia requiring intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Indices of Systolic Function</measure>
    <time_frame>12 weeks and 6 months</time_frame>
    <description>Stroke volume, EF, LV twist, and stress-corrected midwall shortening by echo and 3D multiparametric strain and EF by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LV Hypertrophic Remodeling</measure>
    <time_frame>12 weeks and 6 months</time_frame>
    <description>Relative wall thickness, LV chamber dimensions, and wall thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Novel Echocardiographic Indices of Diastolic Function</measure>
    <time_frame>12 weeks and 6 months</time_frame>
    <description>LV stiffness, viscoelasticity, and a load independent index of diastolic filling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 Minute Walk Distance</measure>
    <time_frame>6 and 12 weeks and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating Neurohormonal Markers</measure>
    <time_frame>6 and 12 weeks and 6 months</time_frame>
    <description>BNP and systemic markers of collagen turnover and oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>6 and 12 weeks and 6 months</time_frame>
    <description>Assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Artery Pressure and Pulmonary Vascular Resistance as Assessed by Echo</measure>
    <time_frame>12 weeks and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic Blood Pressure</measure>
    <time_frame>6 and 12 weeks and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RV Function</measure>
    <time_frame>12 weeks and 6 months</time_frame>
    <description>TAPSE, s' tissue Doppler, and Tei index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AS Severity</measure>
    <time_frame>12 weeks and 6 months</time_frame>
    <description>Aortic valve area, transvalvular pressure gradients</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>LV Remodeling, Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Tadalafil in Diabetic Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Diabetic Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil in Non-Diabetic Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Non-Diabetic Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.</description>
    <arm_group_label>Tadalafil in Diabetic Cohort</arm_group_label>
    <arm_group_label>Tadalafil in Non-Diabetic Cohort</arm_group_label>
    <other_name>Cialis</other_name>
    <other_name>Adcirca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.</description>
    <arm_group_label>Placebo in Diabetic Cohort</arm_group_label>
    <arm_group_label>Placebo in Non-Diabetic Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with moderate to severe aortic stenosis (AVA &lt; 1.5 cm2)

          -  Left ventricular hypertrophy

          -  Diastolic dysfunction as evidenced by tissue Doppler e' (average of septal and
             lateral) ≤ 7 cm/s

          -  EF ≥ 50%

          -  None or minimal symptoms related to aortic stenosis (NYHA ≤ 2)

          -  The subject and treating physician are not planning on a valve replacement procedure
             to occur during the next 6 months

          -  Ambulatory

          -  Normal sinus rhythm

          -  18 years of age and older

          -  Able and willing to comply with all the requirements for the study

        Exclusion Criteria:

          -  Need for ongoing nitrate medications

          -  SBP &lt; 110mmHg or MAP &lt; 75mmHg

          -  Moderately severe or severe mitral regurgitation

          -  Moderately severe or severe aortic regurgitation

          -  Contraindication to MRI

          -  Creatinine clearance &lt; 30 mL/min

          -  Cirrhosis

          -  Pulmonary fibrosis

          -  Increased risk of priapism

          -  Retinal or optic nerve problems or unexplained visual disturbance

          -  If a subject requires ongoing use of an alpha antagonist typically used for benign
             prostatic hyperplasia (BPH) (prazosin, terazosin, doxazosin, or tamsulosin), SBP &lt; 120
             mmHg or MAP &lt; 80 mmHg is excluded

          -  Need for ongoing use of a potent CYP3A inhibitor or inducer (ritonavir, ketoconazole,
             itraconazole, rifampin)

          -  Current or recent (≤ 30 days) acute coronary syndrome

          -  O2 sat &lt; 90% on room air

          -  Females that are pregnant or believe they may be pregnant

          -  Any condition which the PI determines will place the subject at increased risk or is
             likely to yield unreliable data

          -  Unwilling to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian R. Lindman, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <results_first_submitted>October 24, 2018</results_first_submitted>
  <results_first_submitted_qc>April 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2019</results_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic valve stenosis</keyword>
  <keyword>Tadalafil</keyword>
  <keyword>Phosphodiesterase inhibitors</keyword>
  <keyword>Hypertension, pulmonary</keyword>
  <keyword>Hypertrophy, left ventricular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 1, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT01275339/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tadalafil in Diabetic Cohort</title>
          <description>Tadalafil: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.</description>
        </group>
        <group group_id="P2">
          <title>Placebo in Diabetic Cohort</title>
          <description>Placebo: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.</description>
        </group>
        <group group_id="P3">
          <title>Tadalafil in Non-Diabetic Cohort</title>
          <description>Tadalafil: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.</description>
        </group>
        <group group_id="P4">
          <title>Placebo in Non-Diabetic Cohort</title>
          <description>Placebo: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Referred for surgery for AS symptoms</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were a small number of subjects enrolled in this trial before it was terminated. There was block randomization and none got assigned to the Diabetic placebo cohort. Only 2 diabetics were enrolled and they were both randomized to tadalafil.</population>
      <group_list>
        <group group_id="B1">
          <title>Tadalafil in Diabetic Cohort</title>
          <description>Tadalafil: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.</description>
        </group>
        <group group_id="B2">
          <title>Placebo in Diabetic Cohort</title>
          <description>Placebo: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.</description>
        </group>
        <group group_id="B3">
          <title>Tadalafil in Non-Diabetic Cohort</title>
          <description>Tadalafil: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.</description>
        </group>
        <group group_id="B4">
          <title>Placebo in Non-Diabetic Cohort</title>
          <description>Placebo: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="62" upper_limit="68"/>
                    <measurement group_id="B3" value="81.25" lower_limit="62" upper_limit="92"/>
                    <measurement group_id="B4" value="75.5" lower_limit="59" upper_limit="89"/>
                    <measurement group_id="B5" value="75.7" lower_limit="59" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diastolic Function as Measured by Tissue Doppler e'</title>
        <description>Measurement of e' (average of septal and lateral) on echo at each of the time points specified.</description>
        <time_frame>Baseline, 12 weeks, and 6 months</time_frame>
        <population>There were 0 enrolled that were randomized to placebo in the diabetic cohort; the total number enrolled in the study was small, so this happened randomly.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil in Diabetic Cohort</title>
            <description>Tadalafil: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Diabetic Cohort</title>
            <description>Placebo: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil in Non-Diabetic Cohort</title>
            <description>Tadalafil: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.</description>
          </group>
          <group group_id="O4">
            <title>Placebo in Non-Diabetic Cohort</title>
            <description>Placebo: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Function as Measured by Tissue Doppler e'</title>
          <description>Measurement of e' (average of septal and lateral) on echo at each of the time points specified.</description>
          <population>There were 0 enrolled that were randomized to placebo in the diabetic cohort; the total number enrolled in the study was small, so this happened randomly.</population>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" lower_limit="3.52" upper_limit="5.65"/>
                    <measurement group_id="O3" value="5.97" lower_limit="5.00" upper_limit="6.52"/>
                    <measurement group_id="O4" value="5.28" lower_limit="4.48" upper_limit="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" lower_limit="3.21" upper_limit="4.28"/>
                    <measurement group_id="O3" value="6.44" lower_limit="5.31" upper_limit="7.21"/>
                    <measurement group_id="O4" value="4.88" lower_limit="4.36" upper_limit="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" lower_limit="3.91" upper_limit="5.34"/>
                    <measurement group_id="O3" value="6.16" lower_limit="4.77" upper_limit="7.03"/>
                    <measurement group_id="O4" value="5.33" lower_limit="3.57" upper_limit="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Myocardial Fibrosis (ECV) on MRI</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Other Echocardiographic Indices of Diastolic Function</title>
        <description>E/e' and deceleration time</description>
        <time_frame>12 weeks and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability</title>
        <description>The following with be reported - frequency of the following: hypotension (SBP &lt; 90 mmHg), symptomatic hypotension (symptoms of presyncope or syncope associated with SBP &lt;90), syncope, hospitalization for a cardiac reason, myocardial infarction, new onset or worsening heart failure, and new sustained arrhythmia requiring intervention</description>
        <time_frame>6 and 12 weeks and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Indices of Systolic Function</title>
        <description>Stroke volume, EF, LV twist, and stress-corrected midwall shortening by echo and 3D multiparametric strain and EF by MRI</description>
        <time_frame>12 weeks and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LV Hypertrophic Remodeling</title>
        <description>Relative wall thickness, LV chamber dimensions, and wall thickness</description>
        <time_frame>12 weeks and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Novel Echocardiographic Indices of Diastolic Function</title>
        <description>LV stiffness, viscoelasticity, and a load independent index of diastolic filling</description>
        <time_frame>12 weeks and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 6 Minute Walk Distance</title>
        <time_frame>6 and 12 weeks and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Circulating Neurohormonal Markers</title>
        <description>BNP and systemic markers of collagen turnover and oxidative stress</description>
        <time_frame>6 and 12 weeks and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life</title>
        <description>Assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
        <time_frame>6 and 12 weeks and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulmonary Artery Pressure and Pulmonary Vascular Resistance as Assessed by Echo</title>
        <time_frame>12 weeks and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systemic Blood Pressure</title>
        <time_frame>6 and 12 weeks and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in RV Function</title>
        <description>TAPSE, s' tissue Doppler, and Tei index</description>
        <time_frame>12 weeks and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in AS Severity</title>
        <description>Aortic valve area, transvalvular pressure gradients</description>
        <time_frame>12 weeks and 6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>In that arm of the study, no patients were enrolled.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tadalafil in Diabetic Cohort</title>
          <description>Tadalafil: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.</description>
        </group>
        <group group_id="E2">
          <title>Placebo in Diabetic Cohort</title>
          <description>Placebo: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.</description>
        </group>
        <group group_id="E3">
          <title>Tadalafil in Non-Diabetic Cohort</title>
          <description>Tadalafil: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.</description>
        </group>
        <group group_id="E4">
          <title>Placebo in Non-Diabetic Cohort</title>
          <description>Placebo: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>lightheadedness</sub_title>
                <description>Occurred during follow-up</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <description>Unrelated to study drug as blood pressure was fine beforehand</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>unsteady</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>shortness of breath</sub_title>
                <description>Shortness of breath developed during the intervention period</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>orthopnea</sub_title>
                <description>Occurred during follow-up</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>dilated aorta</sub_title>
                <description>Identified in follow-up although it may have been present at baseline</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian R. Lindman, MD</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>615-936-5949</phone>
      <email>brlindman@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

